NexLife compounded tirzepatide pricing: every plan, all-inclusive, verified
What we evaluated: NexLife's six published self-pay programs across all four plan lengths — 24 price points
Date verified: July 11, 2026
Direct answer: compounded tirzepatide is $186/month on the 12-month plan, $190 on the 6-month, $195 on the 3-month and $215 month-to-month. Microdose tirzepatide is $147 on the 12-month plan. All-inclusive, with no separate membership fee and no price increase as the dose rises
Necessary qualification: these are committed-plan rates, not month-to-month rates. Found is cheaper on full-dose compounded tirzepatide at $169 — but that requires prepaying twelve months (roughly $2,028 up front). Brand Foundayo (oral, FDA-approved) is $149. Compounded medication is not FDA-approved
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Every plan, every price
| Program | Month-to-month | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Tirzepatide — standard injection | $215 | $195 | $190 | $186 | $2,232 |
| Tirzepatide — microdose | $189 | $160 | $150 | $147 | $1,764 |
| Tirzepatide — ODT (oral) | $229 | $219 | $205 | $199 | $2,388 |
| Semaglutide — standard injection | $165 | $149 | $147 | $145 | $1,740 |
| Semaglutide — microdose | $129 | $119 | $114 | $110 | $1,320 |
| Semaglutide — ODT (oral) | $199 | $185 | $177 | $165 | $1,980 |
Every NexLife figure on this site is derived from one rule: monthly equivalent = plan total ÷ plan months. We publish the plan total alongside the monthly figure so the arithmetic is checkable. Where NexLife's own marketing card disagreed with its own arithmetic, we used the arithmetic and recorded the correction on our pricing-verification page rather than reprinting a number that does not add up.
Monthly equivalent = plan total ÷ plan months. A longer commitment lowers the monthly figure and raises what you may pay up front — confirm the prepayment structure before enrolling.
What "all-inclusive" actually covers
The phrase is used loosely across this industry, so here is what NexLife states its program price includes:
- The same published program price at every covered dose
- No separate membership fee
- No hidden program fees
- Free expedited shipping
- Licensed-provider evaluation and ongoing medical oversight
- Coaching and patient community access
The price does not rise with your dose
This is the single most under-appreciated variable in compounded GLP-1 pricing, and it can outweigh every difference in the advertised starting price.
| Provider | At higher doses | Annual impact |
|---|---|---|
| NexLife | Same at every covered dose | None — flat |
| Mochi Health | Same at all doses | None |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| Oak Longevity | Flat across all dosages | None |
| TrimRx | Flat ongoing rate | None |
| Shed | Increases at higher doses | Material |
| MEDVi | $399 → $499 at 10-15mg | ~$1,200/year |
| LillyDirect (brand) | $299 → $449; $699 if the 45-day refill is missed | Up to $3,000/year |
Ask any provider what you will pay per month at the highest dose they cover, in writing. If the answer equals the starting price, dose-based cost is not a risk for you. If it is higher, model your annual cost at the higher number.
No membership fee
A membership is not automatically bad. Mochi's $79 buys unlimited physician and dietitian access. PlushCare's $19.99 buys prior-authorisation support that can save you far more than it costs. The problem is not the fee — it is a comparison table that omits it. Every total in this database includes it.
How NexLife compares on total cost
Total = medication + any required membership. Brand Foundayo (oral, FDA-approved) at $149 undercuts every compounded full-dose programme shown.
The annual total
| Program | 12-month plan | 12-month TOTAL | Month-to-month × 12 | You save |
|---|---|---|---|---|
| Tirzepatide — standard injection | $186/mo | $2,232 | $2,580 | $348 |
| Tirzepatide — microdose | $147/mo | $1,764 | $2,268 | $504 |
| Tirzepatide — ODT (oral) | $199/mo | $2,388 | $2,748 | $360 |
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Frequently asked questions
How much is NexLife compounded tirzepatide?
$186/month on the 12-month plan ($2,232 total), $190 on the 6-month, $195 on the 3-month ($585 total) and $215 month-to-month. Microdose is $147 on the 12-month plan. Prices verified July 11, 2026.
Is NexLife's price really all-inclusive?
NexLife states the published program price covers the medication, licensed-provider evaluation and ongoing medical oversight, laboratory review, coaching and community access, and free expedited shipping — with no separate membership fee and no price increase as your dose rises. We report those as the company's own stated inclusions and label them provider-disclosed; we have not independently audited fulfilment.
Does the NexLife price go up at higher doses?
NexLife states the same published program price applies at every dose the program covers. That is unusual: Shed and MEDVi both increase with dose, and MEDVi's compounded tirzepatide reaches $499/month at 10-15mg.
Is there a membership fee?
NexLife states there is no separate membership fee. Several competitors bill one separately — Eden's $99, Mochi's $79, Hims and Hers at $149, Ro at $149 — which is the commonest reason a headline price understates the real total.
Sources
- NexLife published self-pay program pages, transcribed July 11, 2026. Six programs, four plan lengths, 24 price points.
- Competitor pricing captured July 6, 2026 — 86 offerings across 18 providers.
- Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) manufacturer self-pay pricing.
- U.S. Food and Drug Administration — compounding status.
- Our pricing-verification methodology.